stockrow
Friday 6 November 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
- EPS
- +38.6%
- Free cash flow
- +34.8%
Quarter to June 2026, against a year earlier
0.99
0.05
−4.81%
Follow SKYE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to October
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EBT | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) | (50) | +37.5% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) | (50) | +37.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (340.00) | (221.77) | (320.00) | 15.56 | (60.00) | (40.00) | (70.17) | (42.96) | (5.84) | (11.28) | (10.16) | (31.5%) | ||||||
| Cash flow | (373.99) | (237.95) | (65.07) | (89.17) | (52.46) | (31.85) | (45.91) | (15.93) | (5.53) | (8.69) | (7.82) | (34.2%) | ||||||
| Capex | (1.17) | (1.41) | (0.07) | 0.00 | (0.06) | (0.45) | (0.10) | 6.30 | (0.05) | 0.07 | 0.11 | n/m | ||||||
| Free cash flow | (375.16) | (239.36) | (65.14) | (89.17) | (52.52) | (32.30) | (46.01) | (9.63) | (5.59) | (8.61) | (7.71) | (34.3%) | ||||||
| Book value | (152.73) | (57.15) | (256.80) | 8.11 | 3.91 | 28.85 | (10.84) | (2.43) | 14.94 | 4.04 | (0.10) | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 5 | 5 | +100.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (4) | (3) | (4) | (6) | (6) | (6) | (13) | (14) | (25) | (43) | (39) | +31.9% | |||||
| Capex | 0 | 0 | 0 | — | 0 | 0 | 0 | 6 | 0 | 0 | 1 | n/m | ||||||
| Free cash flow | (4) | (3) | (4) | (6) | (6) | (7) | (13) | (8) | (25) | (43) | (38) | +31.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 0 | (14) | 1 | 2 | 6 | (3) | (2) | 66 | 19 | (1) | n/m | |||||
| Net debt | 0 | 0 | 0 | (1) | (2) | (7) | 1 | (6) | (68) | (26) | (10) | +84.8% | ||||||
| Shareholders’ equity | (1) | (1) | (16) | 1 | 0 | 6 | (3) | (2) | 68 | 20 | 0 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (182.72) | (939.88) | (1,526.80) | 53.20 | (281.07) | (136.06) | (205.43) | (357.64) | (62.73) | (110.66) | (159.80) | +72.1 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 184.06 | 127.65 | 200.65 | (14.01) | (1,313.58) | (269.90) | (1,364.21) | 1,464.81 | (80.48) | (126.85) | (233.87) | (310.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 2 | 3 | 3 | 4 | 6 | 9 | 11 | 7 | 16 | 12 | — | +22.0% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Oct 2013 · latest quarter Jul 2014 · fundamentals updated 26 Oct 2026
Skye Bioscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMNN Imunon, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.0M | — (loss-making) | — (loss-making) | +23.79% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,193.84%) | Compare |
| CANF Can-Fite Biopharma Ltd | $4.9M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NIKI Niki BioSolutions, Inc. | $4.7M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $4.6M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.4M | 1.3× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.4M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| Median of peers | $4.8M | — | — | 0.00% | — | +7.61% | 23.77% | 0.00% |
Pay and ownership Proxy statement filed 16 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.36m | (148.28k) | 18.51 |
| 2024 | 6.14m | 2.82m | 69.88 |
| 2023 | 1.81m | 1.25m | 67.16 |
Ownership
Directors and executive officers, together
6.20%
Entities affiliated with
30.90%
Entities affiliated with Versant Venture Capital III, L.P.
7.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement